Fluorobenzene

Repeated dose toxicity: inhalation

Administrative data

Endpoint:

short-term repeated dose toxicity: inhalation

Type of information:

experimental study

Adequacy of study:

disregarded due to major methodological deficiencies

Reliability:

4 (not assignable)

Rationale for reliability incl. deficiencies:

secondary literature

Data source

Reference

Reference 1

Reference Type:

publication

Title:

Toxicological Evaluations Vol. 13

Author:

BG Chemie

Year:

1998

Bibliographic source:

Springer-Verlag Berlin Heidelberg, ISBN 3-540-62658-1

Reference 2

Reference Type:

other: letter

Title:

Letter from Du Pont Chemicals to US EPA submitting reports on studies of fluorobenzene and p-fluorotoluene with attachments (sanitized)

Author:

TSCATS

Year:

1991

Bibliographic source:

Doc ID FYI-OTS-0291-07925, Microfiche No. OTS0000792-1

Materials and methods

Principles of method if other than guideline:

Two-week subacute inhalation study in rats, 10 rats/exposure level, exposure concentrations 0, 200, 750, 2500 ppm, exposure 6 h/day x 2 weeks + 2-week recovery period.

GLP compliance:

not specified

Limit test:

no

Test material

Test material information

Constituent 1

Reference substance name:

Fluorobenzene

EC Number:

207-321-7

EC Name:

Fluorobenzene

Cas Number:

462-06-6

Molecular formula:

C6H5F

IUPAC Name:

fluorobenzene

Test animals

Species:

rat

Strain:

Sprague-Dawley

Sex:

male

Administration / exposure

Route of administration:

inhalation

Type of inhalation exposure:

not specified

Duration of treatment / exposure:

2 weeks, 6 hours/day

Frequency of treatment:

daily

Doses / concentrations

Doses / concentrations 1

Dose / conc.:

200 ppm

Doses / concentrations 2

Dose / conc.:

750 ppm

Doses / concentrations 3

Dose / conc.:

2 500 ppm

No. of animals per sex per dose:

10 males per dose

Control animals:

yes

Results and discussion

Target system / organ toxicity

Critical effects observed:

not specified

Any other information on results incl. tables

PRELIMINARY RESULTS:

Exposure to 2500 ppm caused reduced body weight gain but no other symptoms. The relative liver weight was increased in the 2500 ppm group after the final inhalation exposure, but returned to normal again within the observation period. Exposure to 2.000 and 750 ppm caused a reduction in blood calcium and all concentrations led to a decrease in triglycerides and an increase in the fluoride level in the plasma and the urine. The triglyceride levels were still elevated in the group exposed to the highest concentration after the 2-week observation period but the effect showed a tendency towards reversibility, the same applying to the increased excretion of fluoride in the urine. Based on these findings an "acceptable exposure limit" (AEL) of 10 ppm (equivalent to 39.2 mg/ml) was set within the company.